{"id":"caiv-t-liquid","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal congestion"},{"rate":null,"effect":"Runny nose"},{"rate":null,"effect":"Sore throat"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAIV-T contains temperature-sensitive, attenuated influenza virus strains that replicate in the cooler upper respiratory tract but not in warmer lower respiratory tissues, triggering both local mucosal immunity and systemic antibody responses. The vaccine is designed to provide protection against seasonal influenza strains while minimizing systemic reactogenicity associated with inactivated vaccines.","oneSentence":"CAIV-T is a live attenuated influenza vaccine administered as a nasal spray that stimulates mucosal and systemic immune responses against influenza.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:42.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in children and adults"}]},"trialDetails":[{"nctId":"NCT00192387","phase":"PHASE2","title":"Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":60},{"nctId":"NCT00192192","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-11","conditions":"Influenza","enrollment":20},{"nctId":"NCT00192231","phase":"PHASE3","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-04","conditions":"Influenza","enrollment":120},{"nctId":"NCT00128167","phase":"PHASE3","title":"Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-10","conditions":"Influenza","enrollment":8500},{"nctId":"NCT00192153","phase":"PHASE2","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-07","conditions":"Influenza","enrollment":240},{"nctId":"NCT00192413","phase":"PHASE3","title":"Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-03","conditions":"Influenza","enrollment":3009},{"nctId":"NCT00192179","phase":"PHASE2","title":"A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2003-06","conditions":"Influenza","enrollment":240},{"nctId":"NCT00192322","phase":"PHASE2","title":"Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":173},{"nctId":"NCT00192309","phase":"PHASE2","title":"Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":31},{"nctId":"NCT00224783","phase":"PHASE1","title":"Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-08","conditions":"Healthy Japanese Male Adults","enrollment":45},{"nctId":"NCT00192166","phase":"PHASE2","title":"Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-10","conditions":"Influenza","enrollment":1200},{"nctId":"NCT00192400","phase":"PHASE3","title":"Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-03","conditions":"Healthy","enrollment":2160},{"nctId":"NCT00217230","phase":"PHASE3","title":"Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-04","conditions":"Influenza","enrollment":3000},{"nctId":"NCT00192244","phase":"PHASE3","title":"Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2000-09","conditions":"Healthy","enrollment":3000},{"nctId":"NCT00192426","phase":"PHASE3","title":"Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":2400},{"nctId":"NCT00192374","phase":"PHASE3","title":"Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-02","conditions":"Healthy","enrollment":1920}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CAIV-T, Liquid","genericName":"CAIV-T, Liquid","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAIV-T is a live attenuated influenza vaccine administered as a nasal spray that stimulates mucosal and systemic immune responses against influenza. Used for Seasonal influenza prevention in children and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}